Health & Biotech
Compumedics is a leading global, innovative developer/designer and manufacturer of medical technology, devices, health services and supplies for:
- Diagnosing sleep disorders, including our new Somfit SaaS technology platform
- Monitoring neurological disorders and highly sophisticated brain analysis, including is new MEG technology.
- Ultrasonic monitoring of blood flow through the brain.
Compumedics has sold more than 30,000 devices globally through our direct sales offices, in Australia, USA, France and Germany, and a distribution network of about 100 distributors covering all other parts of the world. Since listing on the Australian Securities Exchange (ASX) in December 2000 these sales have generated more than $800m in revenues, of which more than $700m has been export revenues.
Importantly Compumedics has in recent years focused on Software as a Service (SaaS) in both its sleep and neurology markets and has to date generated, through its SaaS, over 200,000 Lab and/or home-based sleep studies and about 8,000 lab and/or home-based neurology studies. This has taken annual SaaS revenues from nothing to about $1.0m last year, with the expectation that Compumedics is well positioned for rapid scaling in this area, particularly in the USA and Australia.
Compumedics is based in Australia with offices in Melbourne, Australia (Home Office), Charlotte NC, USA, Hamburg, Singen and Freiburg, Germany, Paris, France, Vienna, Austria and Daejon, South Korea.
Compumedics has about 145 staff around the world.
Executive Chairman Dr David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.
Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Stockhead TV
Road to 2025: Global success for this MedTech
Health & Biotech
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drug
Health & Biotech
Health Check: Biotech’s forgotten tortoises pick up the pace as sector emerges from two-year slump
Health & Biotech
Health Check: It’s goodbye to ugly grey ‘gob filler’ as SDI’s aesthetic alternative gains traction
Health & Biotech
Alive and Kicking: ‘We are not alone in going through a lull in markets’, says Clinuvel chair
News
Market Highlights: Analysts see Nvidia as good pick up, and why investors will be on edge tonight
Health & Biotech
Wake Up! Don’t get caught sleeping on these three dreamy stocks
Health & Biotech
ASX Health Stocks: Amplia sees new success in pancreatic cancer trial
News
Market Highlights: Not much spared on chopping block after another big selloff, Wall Street loses US$3.5 trillion
Health & Biotech
Dr Boreham’s Crucible: Sleep diagnostics stayer is still dreaming big
News
CLOSING BELL: Big Coal fires up the Energy sector, but not enough to stop the rot
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
Health & Biotech
Check Up: Earnings season is almost here. Here’s how ASX biotech investors should read the 4C Report
News
Hot Money Monday: Beware of ‘mean reversion’ as Compumedics, Fatfish surge on momentum
News
In Case You Missed It: Iron ore, oil fields and medical diagnostics deals
News